MESENCHYMAL STEM CELLS THERAPY FOR PATIENTS WITH PREMATURE OVARIAN FAILURE
Premature ovarian failure (FOP) also known as premature menopause refers to a condition characterized by estrogen deficiency, menopause symptoms (Lack of menstruation for more than a year, changes in mood, changes in skin or hair, etc.). It occurs in women under the age of 40 and causes fertility problems in addition to increasing the risk of cardiovascular disease, osteoporosis and sexual dysfunction. Fortunately Dr. Romo at Dream Body Clinic is a skilled OB/GYN that can reverse these symptoms with a mesenchymal stem cells treatment.
What is the Premature Ovarian Failure Stem Cell Treatment?
This procedure is done in the operating room under general anesthesia. He can only perform this procedure on the 14th day of the patients menstral cycle. Dr. Romo uses ultrasound to guide a line to the ovary. He then injects 25 million stem cells mixed with platelet rich plasma (PRP). He then does the same for the other ovary. So a total of 50 million mesenchymal stem cells are administered.
The Following things need to be analyzed pre-treatment
- Ovarian profile (FSH, LH, FOP suggestive estradiol).
- Hematic biometrics, coagulation times.
- If you have any chronic conditions, recent studies related to pathology to confirm control or initiate treatment if necessary.
What care is needed post-procedure?
- This treatment will require 1 night hospitalization for medical surveillance. This is included in the package.
- Dr. Romo advises that patients abstain from sexual intercourse for 1 week post treatment.
How is the diagnosis of Premature Ovarian Failure performed?
In order to be considered that a woman is with FOP, she must meet the following criteria:
- Be under 40 years old
- FSH laboratory test greater than 30 in 2 samples with separation of at least 4 weeks.
- Symptoms of pre-menopause such as menstrual cycle disturbances, decreased libido,hot flashes, mood swings and others.
How do Mesenchymal Stem Cells (MSCs) work in FOP treatment?
The regenerative properties of MSCs have been recognized, have been seen to reduce programmed cell death by helping to regain ovarian function and increasing the amount of circulating sex hormones. Multiple pre-clinical studies showed no increase in the quantity and quality of eggs produced in the ovaries of women diagnosed with FOP and ultrasound lytrated increased blood flow to the ovaries.
In a randomized clinical trial in China, in which 16 women with fertility problems due to premature ovarian failure were included, it was decided to use MSCs by direct application to the ovaries vaginally as an alternative treatment to improve the chance of pregnancy and were given follow-up at 3 months, achieving the above-mentioned improvements. Half of patients (8) supplemented the use of MSCs with collagen to stability and lengthen the permanence of MSCs in ovarian tissue. As a result of this clinical trial, 62.5% of patients using MSCs with collagen were able to develop ovulation and of all 16 patients, 2 had spontaneous pregnancies and 1 achieved a healthy full-term pregnancy.
View the Study Here – premature ovarian failure stem cell therapy study dream body clinic
and the other study here – https://link.springer.com/article/10.1007%2Fs11427-017-9272-2
There has also been benefit for patients who wish to achieve pregnancy and suffer from uterine adhesion syndrome and have poor endometrial conditions to achieve an adequate implantation of an embryo produced by abortions or infertility. The application of MSCs has shown increased vascularity of the endometrium and therefore the quality of it.
The application of MSCs in this case is done vaginally with a cannula inside the uterus with follow-up at 3 months.